Audentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 12, 2017, the Board of Directors (the “Board”) of Audentes Therapeutics, Inc. (the “Company”) appointed Jennifer Jarrett as a Class I director, effective as of the same date.

Ms. Jarrett will receive an annual cash retainer of $35,000 per year in accordance with the Company’s existing compensation policy for non-employee directors. In addition, the Board granted to Ms. Jarrett, effective as of June 12, 2017, a stock option to purchase 18,000 shares of common stock, which will vest monthly over three years, subject to Ms. Jarrett’s continued service to the Company.

The Company has entered into its standard form of indemnification agreement with Ms. Jarrett. A form of the indemnification agreement was previously filed by the Company as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 11, 2016.  

There is no arrangement or understanding with any person to which Ms. Jarrett was appointed as a member of the Board, and Ms. Jarrett does not have any direct or indirect material interest in any transaction required to be disclosed to Item 404(a) of Regulation S-K.  


About Audentes Therapeutics, Inc. (NASDAQ:BOLD)

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.